GLAXO - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.7
| Stock Code | GLAXO | Market Cap | 39,509 Cr. | Current Price | 2,333 ₹ | High / Low | 3,500 ₹ |
| Stock P/E | 43.5 | Book Value | 132 ₹ | Dividend Yield | 2.44 % | ROCE | 61.3 % |
| ROE | 43.3 % | Face Value | 10.0 ₹ | DMA 50 | 2,302 ₹ | DMA 200 | 2,476 ₹ |
| Chg in FII Hold | -0.01 % | Chg in DII Hold | -0.02 % | PAT Qtr | 275 Cr. | PAT Prev Qtr | 277 Cr. |
| RSI | 60.2 | MACD | -30.1 | Volume | 2,78,958 | Avg Vol 1Wk | 2,40,114 |
| Low price | 2,088 ₹ | High price | 3,500 ₹ | PEG Ratio | 2.78 | Debt to equity | 0.01 |
| 52w Index | 17.3 % | Qtr Profit Var | 5.69 % | EPS | 59.7 ₹ | Industry PE | 32.5 |
📊 GlaxoSmithKline Pharma shows strong efficiency with high [ROCE](ca://s?q=Explain_ROCE) (61.3%) and [ROE](ca://s?q=Explain_ROE) (43.3%), reflecting excellent capital utilization. The company is nearly debt-free (0.01 debt-to-equity), which adds financial stability. However, the [P/E valuation](ca://s?q=Explain_P/E_ratio) of 43.5 is significantly above the industry average (32.5), and the [PEG ratio](ca://s?q=Explain_PEG_ratio) of 2.78 indicates growth is priced at a premium. Dividend yield (2.44%) provides decent income support, but quarterly PAT (275 Cr vs 277 Cr) shows flat growth.
💡 The ideal entry price zone would be near 2,100–2,250 ₹, close to the 52-week low (2,088 ₹) and below DMA levels (2,302–2,476 ₹), offering a margin of safety. RSI (60.2) suggests the stock is approaching overbought territory, while MACD (-30.1) indicates bearish momentum, making dips more favorable for accumulation.
📈 For existing holders, a long-term horizon of 3–5 years is recommended, given strong efficiency and dividend support. Exit strategy: consider partial profit booking if the stock revisits 3,200–3,400 ₹, while retaining core holdings for sustained growth. Dividend yield provides stability, but valuation risks warrant caution.
✅ Positive
- 📌 High ROCE (61.3%) and ROE (43.3%) reflect strong efficiency.
- 📌 Debt-free balance sheet ensures resilience.
- 📌 Dividend yield of 2.44% adds income stability.
⚠️ Limitation
- 📌 Elevated P/E ratio (43.5) compared to industry average (32.5).
- 📌 PEG ratio of 2.78 indicates growth is expensive.
- 📌 Flat quarterly PAT (275 Cr vs 277 Cr) shows limited momentum.
- 📌 Slight decline in both FII (-0.01%) and DII (-0.02%) holdings.
📉 Company Negative News
- 📌 No major negative news reported, but valuation risks remain high.
📈 Company Positive News
- 📌 Strong efficiency metrics and consistent dividend payouts.
🏭 Industry
- 📌 Industry P/E at 32.5, lower than Glaxo’s 43.5, suggesting overvaluation.
- 📌 Pharma sector benefits from steady demand and regulatory support.
🔎 Conclusion
GlaxoSmithKline Pharma is a fundamentally strong but relatively expensive candidate for long-term investment. The ideal entry zone is 2,100–2,250 ₹. Current holders should maintain positions for 3–5 years, with partial profit booking near 3,200–3,400 ₹ while retaining core shares for dividend stability and long-term growth.